Metabolomics

Dataset Information

0

GNPS - Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis

ABSTRACT: Non-alcoholic fatty liver disease is now considered the most common form of chronic liver disease. It is a complex metabolic disease that silently progresses into non-alcoholic steatohepatitis (NASH). In fact, NASH is the tipping point for pericellular fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Despite being a complex metabolic disease, identification of the metabolic readout that functions in metabolic pathway perpetuation for HCC progression from NASH is still incompletely understood. With the aid of LC MS/MS this study unveiled the metabolic fingerprint of NASH and HCC-NASH patients and it illustrates a detailed map for the most predominant reprogrammed metabolic pathways that target HCC development from NASH. https://doi.org/10.3390/ijms24010210

INSTRUMENT(S): TripleTOF 5600+

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Sameh Magdeldin  

PROVIDER: MSV000088003 | GNPS | Thu Aug 19 06:51:00 BST 2021

REPOSITORIES: GNPS

Json Xml

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1
altmetric image

Publications

Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis.

Ahmed Eman A EA   El-Derany Marwa O MO   Anwar Ali Mostafa AM   Saied Essa M EM   Magdeldin Sameh S  

International journal of molecular sciences 20221222 1

With the rising incidence of hepatocellular carcinoma (HCC) from non-alcoholic steatohepatitis (NASH), identifying new metabolic readouts that function in metabolic pathway perpetuation is still a demand. The study aimed to compare the metabolic signature between NASH and NASH-HCC patients to explore novel reprogrammed metabolic pathways that might modulate cancer progression in NASH patients. NASH and NASH-HCC patients were recruited and screened for metabolomics, and isotope-labeled lipidomics  ...[more]

Similar Datasets

Proteomics Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis
2021-08-19 | MSV000088003 | MassIVE
Transcriptomics Microarray analysis among non-alcoholic fatty liver, non-alcoholic steatohepatitis, and type 2 diabetes mellitus rats
2015-01-23 | E-GEOD-65220 | biostudies-arrayexpress
Transcriptomics Expression data from human non-alcoholic fatty liver disease stages
2014-11-07 | E-GEOD-63067 | biostudies-arrayexpress
Transcriptomics Microarray analysis among non-alcoholic fatty liver, non-alcoholic steatohepatitis, and type 2 diabetes mellitus rats
2015-01-23 | GSE65220 | GEO
Transcriptomics The methyltransferase MLL4 promotes non-alcoholic steatohepatitis by enhancing NF-κB signaling
2024-11-18 | GSE277545 | GEO
Transcriptomics Post-transplant (non-alcoholic steatohepatitis) NASH compared with transplanted normal controls
2022-05-09 | E-MTAB-11688 | biostudies-arrayexpress
Transcriptomics Expression data from human non-alcoholic fatty liver disease stages
2014-11-07 | GSE63067 | GEO
Transcriptomics Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice
2019-06-07 | GSE129306 | GEO
Transcriptomics Different expression of non-alcoholic fatty liver disease in rats induced by high-fat diet
2023-01-09 | GSE222093 | GEO
Transcriptomics Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease
2022-02-01 | GSE163471 | GEO